Kulvinder Kochar Kaur*, Gautam Nand Allahbadia and Mandeep Singh

Department of Obstetrics and Gynecology, Specialist Reproductive Endocrinology and Infertility Specialist, Scientific Director cum Owner Dr Kulvinder Kaur Centre For Human Reproduction Scientific Director Cum Owner, T. B. Punjab, India

*Corresponding Author: Kulvinder Kochar Kaur, Department of Obstetrics and Gynecology, Specialist Reproductive Endocrinology and Infertility Specialist, Scientific Director cum Owner Dr Kulvinder Kaur Centre For Human Reproduction Scientific Director Cum Owner, T. B. Punjab, India.

Received: April 10, 2025; Published:April 29, 2025

Abstract

Non-alcoholic fatty liver disease (NAFLD) portrays an escalating public health botheration with its prevalence along with an incidence escalating worldwide till6-35% in adults population. Earlier we reviewedhow Vitamin D, its receptors, allyl isothiocyanate, combination, of L-Carnitine (LC), Nicotinamide Ribose (NR), sodium dependent astragaloside IV and apical bile acid transporter (ASBT) or volixibat and silybin, probiotics and synbiotics, astragaloside IV, various prospective agents like Obeticholic Acid (OCA)etc, targeting gut microbiota. Of these other than silybin, probiotics and synbiotics, none of are getting used in clinical scenario. Thus need for generating innovative therapeutic targes for treating NAFLD/non alcoholic steatohepapititis (NASH), exists. Recent studies have pointed that ferroptosis, iron based cell demise has been tobe implicated in generating NAFLD. Additionally, Melatonin (Mel) displayed plausible advantages in avoidance of generation and of liver diseases. Here we have illustrated how Mel might be efficacious in the NAFLD treatment in a mouse model byhampering hepatic ferroptosis. Regarding mechanistic modes , MT2, however not MT1 was implicated in the actions of Mel . Moreover, Mel therapy hampered HFD or erastin activated ER stress and activated protein kinase A (PKA)/IRE1 signaling pathway. Coexpression of phosphorylated (p)- PKA and p-IRE1 got escalated by MT2 antagonist. Hampering agents of PKA and IRE1 respectively led to improvement of hepatic ferroptosis and activation of cyclic adenosine mono phosphate (cAMP )/IRE1 possessed the capacity of reverting Mel’s actions on ferroptosis. Thereby pointing that exogenous Mel hampers hepatic ferroptosis in NAFLD by attenuating ERstress via MT2/ cAMP/PKA)/IRE1 pathway , that validates Mel attractive candidate agent therapy of hepatic ferroptosis in NAFLD. However in future human studies need to validate this.

Keywords: Non-Alcoholic Fatty Liver Disease (NAFLD); Hepatic Ferroptosis; Melatonin (Mel); MT2; ER Stress

References

1. Kulvinder Kochar Kaur., et al. “A Mini Review on Development of Newer Therapies for Non Alcoholic Fatty Acid Liver Disease with Emphasis on Vitamin D and its Receptor and Allyl Isothiocyanate (AITC)". Acta Scientific Nutritional Health 3.12 (2019): 1-5.
2. Kulvinder Kochar Kaur., et al. “An Update on Further Progression of NAFLD, NASH with Prospective Therapies Like L-Carnitine (LC), Nicotinamide Ribose (NR) Combination, as well as Apical Sodium Dependent Bile Acids Transporter (ASBT) or Volixibat and Silybin as Alternatives”. The International Journal of Clinical and Medical Cases 3.3 (2020): 138.
3. Kulvinder Kochar Kaur., et al. “Have Probiotics and Synbiotics passed the test of time to be implemented in management of obesity and related metabolic disorders-a comprehensive review”. Advances in Obesity, Weight Management and Control 9.1 (2019): 21-28.
4. Kulvinder Kochar Kaur., et al. “Will Probiotics Provide the Answer for Therapy of Non-alcoholic Fatty Liver Disease (NAFLD)? - A Systematic Review”. Journal of Physiology and Biochemistry 9 (2020): 257.
5. Kulvinder Kochar Kaur., et al. “Rosmarinic Acid-A New Hope for Liver Diseases Like Cirrhosis, Hepatocellular Carcinoma-NeedsTranslation to Humans”. EC Endocrinology and Metabolic Research 4.6 (2019): 289-301.
6. Kulvinder Kochar Kaur., et al. “How do we apply advances in knowledge of Hepatic Macrophages in treating Liver Diseases especially non alcoholic  fatty liver disease (NAFLD), non-alcoholic steatohepapititis( NASH), with the increasing incidence of Diabesity-A Systematic Review”. EC Endocrinology and Metabolic Research (2020).
7. Kulvinder Kochar Kaur., et al. “Mechanisms that associate extension of Nonalcoholic fatty liver diseases(NAFLD) to NASH (Non-alcoholic steatohepatitis) and further progressing to cirrhosis and Hepatocellular carcinoma(HCC) in addition to few proposed biomarkers for poor prognosis”. Journal of Gynecology 1.16 (2021): 1-18.
8. Kulvinder Kochar Kaur., et al. “How can we optimize therapy of Non-Alcoholic Fatty Acid Liver Disease-A Short Communication on role of Astragaloside IV and other prospective agents”. Clinical Research and Clinical Case Reports 1.3 (2021): 1-4.
9. Kulvinder Kochar Kaur., et al. “Paradoxical Additional Role of SGLT2 Inhibitors Beyond Glycosuria in Controlling Obesity, NAFLD Treatment, Pancreatic β Cell Protection Besides Therapy for Diabetes Mellitus, CVOT and Renoprotection-A Minireview". Acta Scientific Gastrointestinal Disorders 4.7 (2021): 15-26.
10. Kulvinder Kochar Kaur M., et al. “An update on management of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepapititis-Is  the time ripe for achieving  resolution of NAFLD and NASH soon”.  Journal of Endocrinology Research 3.2 (2021): 44-60.
11. Kulvinder Kochar Kaur., et al. “The Association of Non-Viral Liver Diseases from NAFLD to NASH to HCC with the Pandemic of  Obesity ,Type 2 Diabetes, or Diabesity and Metabolic Syndrome -Etiopathogenetic Correlation along with Utilization for Diagnostic and Therapeutic Purposes-A Systematic review’’. Journal of Endocrinology Research 3.2 (2021): 10-34.
12. Kulvinder Kochar Kaur, ., et al. “An update on the etiopathogenesis of NAFLD including Organokines for early diagnosis and improvement of management and  preventing early HCC development: A narrative review”. Liver Research - Open Journal 4.1 (2023): 18-41.
13. Kulvinder Kochar Kaur., et al. “An update on Targeting Gut Microbiota (GM) for Avoidance of Metabolic dysfunction associated steatohepatitis propagation to Hepatocellular Carcinoma-A Narrative Review”. MAR Clinical Case Reports 5 (2023): 9.
14. Kulvinder Kochar Kaur., et al. “Combined use of   Cell Death Mechanisms as plausible therapeutic  targets with canonical therapies for Breast Cancer: potentially  decreasing  dose, toxicity, expenditure and improved  survival -A narrative review”. under review (2023).
15. Younossi Z., et al. “Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention”. Nature Reviews Gastroenterology and Hepatology 15 (2018): 11-20.
16. Yip T., et al. “Asian perspectives on NAFLD associated HCC”. Journal of Hepatology 76 (2022): 72-34.
17. Ji J., et al. “Gut microbiome and ferroptosis in MAFLD”. Clinical and Translational Gastroenterology 11 (2023): 174-187.
18. Zhou J., et al. “Epidemiological  features of NAFLD from 1999 to2018 in China”. Hepatology  71 (2020): 1851-1864.
19. Tang D., et al. “Ferroptosis:  mechanisms, and health  implications”. Cell Research 31 (2021): 107-125.
20. Chen X., et al. “Characteristics and biomarkers of ferroptosis”. Frontiers in Cell and Developmental Biology 9 (2021):  637162.
21. Zheng J and Conrad M. “The metabolic  underpinnings of ferroptosis”. Cell Metabolism 39 (2020): 920-937.
22. Wu S., et al. “Macrophage extracellular   traps   aggravate  iron load  related liver ischaemia reperfusion injury”. British Journal of Pharmacology 169 (2013): 92232.
23. Qi J., et al. “Ferroptosis affects the progression of non alcoholic steatohepapititis viathe modulation of lipid peroxidation- mediated cell death in mice”. The American Journal of Pathology 190 (2020): 68-91.
24. Zhang X., et al. “Resveratrol protected  acrolein induced ferroptosis and insulin secretion dysfunction   via ER stress related PERKpathway inMIN6cells”. Toxicology  465 (2022): 153048.  
25. Jiang D., et al. “Targeting the IRE1/XBP1 branches of the unfolded   protein response  in human diseases”. Seminars in Cancer Biology 33 (2015): 45-56.
26. Wei R., et al. “Taginin C  induces ferroptosis through PERK- Nrf2-HO signaling  pathway in colorectal cancer cells”. International Journal of Biological Sciences 17 (2021):  2703-2717.
27. Liu J., et al. “MT1 and MT2 membrane receptors:a  therapeutic perspective”. Annual Review of Pharmacology and Toxicology 56 (2016): 361-383.
28. Wang X., et al. “Melatonin alleviates acute ,sleep deprivation induced memory loss in mice  by supressing  hippocampal ferroptosis”. Frontiers in Pharmacology 12 (2021): 708645.  
29. Guohua F., et al. “Melatonin  protects s against PM 2.5  induced lungs injury  by inhibiting ferroptosis  of  lung epithelial cells in a    Nrf2 dependent manner”. Ecotoxicology and Environmental Safety 223 (2021): 112588.
30. Guan Q., et al. “Melatoninameliorates hepatic ferroptosis in NAFLD by inhibiting  ERstress viathe MT2/cAMP/PKA)/IRE1 signaling pathway”. International Journal of Biological Sciences 19 (2023): 3937-3950.

Citation

Citation: Kulvinder Kochar Kaur., et al. “Melatonin as a Future Prospective Therapy for Nonalcoholic Fatty Liver Disease by Targeting Hepatic Ferroptosis: A Short Communication".Acta Scientific Gastrointestinal Disorders 8.5 (2025): 35-45.

Copyright

Copyright: © 2025 Kulvinder Kochar Kaur., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.